PolarityTE Competitors

Surface Oncology (NASDAQ:SURF) and PolarityTE (NASDAQ:PTE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Surface Oncology and PolarityTE, as reported by MarketBeat.com.

Surface Oncology currently has a consensus target price of $12.00, indicating a potential upside of 61.29%. PolarityTE has a consensus target price of $4.00, indicating a potential upside of 214.96%. Given PolarityTE's higher possible upside, analysts clearly believe PolarityTE is more favorable than Surface Oncology.

Institutional and Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. Comparatively, 16.5% of PolarityTE shares are owned by institutional investors. 35.0% of Surface Oncology shares are owned by insiders. Comparatively, 5.5% of PolarityTE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Surface Oncology has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, PolarityTE has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Valuation and Earnings

This table compares Surface Oncology and PolarityTE's gross revenue, earnings per share and valuation.

Surface Oncology has higher revenue and earnings than PolarityTE. Surface Oncology is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Surface Oncology and PolarityTE's net margins, return on equity and return on assets.

Summary

Surface Oncology beats PolarityTE on 10 of the 12 factors compared between the two stocks.

Checkmate Pharmaceuticals (NASDAQ:CMPI) and PolarityTE (NASDAQ:PTE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Checkmate Pharmaceuticals and PolarityTE, as reported by MarketBeat.

PolarityTE has a consensus target price of $4.00, indicating a potential upside of 214.96%. Given PolarityTE's higher possible upside, analysts plainly believe PolarityTE is more favorable than Checkmate Pharmaceuticals.

Valuation & Earnings

This table compares Checkmate Pharmaceuticals and PolarityTE's revenue, earnings per share and valuation.

Checkmate Pharmaceuticals has higher earnings, but lower revenue than PolarityTE.

Institutional & Insider Ownership

75.6% of Checkmate Pharmaceuticals shares are held by institutional investors. Comparatively, 16.5% of PolarityTE shares are held by institutional investors. 5.5% of PolarityTE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Checkmate Pharmaceuticals and PolarityTE's net margins, return on equity and return on assets.

Summary

Checkmate Pharmaceuticals beats PolarityTE on 7 of the 10 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 68.8% of Eiger BioPharmaceuticals shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 5.8% of Eiger BioPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares PolarityTE and Eiger BioPharmaceuticals' revenue, earnings per share (EPS) and valuation.

Eiger BioPharmaceuticals has lower revenue, but higher earnings than PolarityTE. Eiger BioPharmaceuticals is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for PolarityTE and Eiger BioPharmaceuticals, as provided by MarketBeat.com.

PolarityTE currently has a consensus price target of $4.00, indicating a potential upside of 214.96%. Eiger BioPharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 176.85%. Given PolarityTE's higher possible upside, equities analysts clearly believe PolarityTE is more favorable than Eiger BioPharmaceuticals.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Profitability

This table compares PolarityTE and Eiger BioPharmaceuticals' net margins, return on equity and return on assets.

Summary

Eiger BioPharmaceuticals beats PolarityTE on 9 of the 12 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and PDL BioPharma (NASDAQ:PDLI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 86.2% of PDL BioPharma shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 2.2% of PDL BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares PolarityTE and PDL BioPharma's top-line revenue, earnings per share (EPS) and valuation.

PDL BioPharma has higher revenue and earnings than PolarityTE. PolarityTE is trading at a lower price-to-earnings ratio than PDL BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for PolarityTE and PDL BioPharma, as provided by MarketBeat.

PolarityTE presently has a consensus price target of $4.00, indicating a potential upside of 214.96%. Given PolarityTE's higher possible upside, research analysts clearly believe PolarityTE is more favorable than PDL BioPharma.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, PDL BioPharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Profitability

This table compares PolarityTE and PDL BioPharma's net margins, return on equity and return on assets.

Summary

PDL BioPharma beats PolarityTE on 7 of the 13 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 24.8% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares PolarityTE and CASI Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

CASI Pharmaceuticals has lower revenue, but higher earnings than PolarityTE. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for PolarityTE and CASI Pharmaceuticals, as provided by MarketBeat.

PolarityTE presently has a consensus price target of $4.00, indicating a potential upside of 214.96%. CASI Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 87.22%. Given PolarityTE's higher possible upside, research analysts clearly believe PolarityTE is more favorable than CASI Pharmaceuticals.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Profitability

This table compares PolarityTE and CASI Pharmaceuticals' net margins, return on equity and return on assets.

Summary

CASI Pharmaceuticals beats PolarityTE on 9 of the 13 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Valuation & Earnings

This table compares PolarityTE and Cabaletta Bio's top-line revenue, earnings per share (EPS) and valuation.

Cabaletta Bio has lower revenue, but higher earnings than PolarityTE. Cabaletta Bio is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 68.0% of Cabaletta Bio shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 6.5% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for PolarityTE and Cabaletta Bio, as provided by MarketBeat.

PolarityTE presently has a consensus price target of $4.00, indicating a potential upside of 214.96%. Cabaletta Bio has a consensus price target of $20.3333, indicating a potential upside of 80.26%. Given PolarityTE's higher possible upside, research analysts clearly believe PolarityTE is more favorable than Cabaletta Bio.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Profitability

This table compares PolarityTE and Cabaletta Bio's net margins, return on equity and return on assets.

Summary

Cabaletta Bio beats PolarityTE on 9 of the 13 factors compared between the two stocks.